A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.

@article{Luthringer1996ADP,
  title={A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.},
  author={R. Luthringer and Michel Toussaint and N Schaltenbrand and P. K. Bailey and P H Danjou and David Hackett and J Y Guichoux and J. P. Macher},
  journal={Psychopharmacology bulletin},
  year={1996},
  volume={32 4},
  pages={637-46}
}
Venlafaxine, a member of a novel chemical class, phenethylamines, is a new antidepressant that inhibits neuronal uptake of serotonin, norepinephrine, and dopamine (in decreasing order of potency) at doses of 75 to 375 mg per day. Depression and antidepressant drugs are known to modify human sleep patterns. Our objective in this double-blind, placebo-controlled study was to assess the effects of venlafaxine on polysomnographic variables by comparing the effects of venlafaxine and placebo on… CONTINUE READING